NextFin News - Eli Lilly is scheduled to report its first-quarter earnings for 2026 before the opening bell on Thursday, a release that has become a bellwether for the high-stakes weight-loss drug market. Wall Street analysts surveyed by LSEG expect the pharmaceutical giant to post adjusted earnings per share of $6.66 on revenue of $17.62 billion. The report arrives at a critical juncture for the company, as its stock has retreated roughly 20% since the start of the year, reflecting a shift in investor sentiment from pure growth optimism to execution-focused scrutiny.
The primary engine of Lilly’s growth remains its GLP-1 franchise. Analysts polled by StreetAccount anticipate that Zepbound, the company’s blockbuster obesity treatment, will generate $4.04 billion in quarterly sales, with the vast majority—$3.98 billion—originating from the U.S. market. Its diabetes counterpart, Mounjaro, is expected to book worldwide sales of $7.26 billion. These figures represent a significant year-over-year acceleration, yet the market’s focus has shifted toward the sustainability of these margins under a new political and competitive landscape.
David Risinger, an analyst at Leerink Partners, noted in a recent report that early prescription data for Lilly’s newly approved oral GLP-1, Foundayo, suggests a "modest" initial rollout. Risinger, who maintains a cautious but data-driven stance on the sector's near-term scaling, pointed out that Foundayo recorded approximately 1,390 U.S. prescriptions in its early phase, trailing the 3,071 prescriptions seen for Novo Nordisk’s rival Wegovy pill during a similar timeframe. This performance gap has already prompted some analysts to slash 2026 revenue forecasts for the oral drug to a range of $1.3 billion to $1.6 billion, down from earlier, more aggressive estimates of $4 billion to $5 billion.
Risinger’s assessment is not yet a consensus view, as some bulls argue that Lilly’s manufacturing expansion will eventually overwhelm these early distribution bottlenecks. However, his focus on "prescription flow versus revenue flow" highlights a growing skepticism regarding whether Lilly can maintain its premium valuation if the oral pill launch fails to match the explosive trajectory of its injectable predecessors. The company’s ability to scale production remains the ultimate arbiter of its top-line success, even as demand appears virtually bottomless.
Beyond internal execution, external pressures are mounting. U.S. President Trump has signaled a renewed focus on drug pricing transparency and domestic manufacturing incentives, which could impact Lilly’s long-term pricing power. CEO Dave Ricks acknowledged in late April that while lower prices—driven by government deals and cash-pay discounts—might squeeze immediate margins, they are expected to accelerate prescription volumes by broadening patient access. This volume-over-price strategy will be tested as Medicare coverage for obesity drugs begins to come online later this year.
The quarterly results will also be weighed against a broader pharmaceutical sector that has outperformed Lilly by nearly 11% over the past month. While the company has beaten earnings estimates for five consecutive quarters, the market's reaction to a "beat and raise" is no longer guaranteed. Investors are now demanding clarity on how Lilly will navigate a second half of the year defined by increased competition from Novo Nordisk and a shifting regulatory environment in Washington. The results delivered this morning will determine if Lilly can reclaim its status as the sector's undisputed leader or if the "GLP-1 premium" is finally beginning to fade.
Explore more exclusive insights at nextfin.ai.
